# Novo Nordisk A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Novo Nordisk A/S). ## Overview Novo Nordisk A/S is a Denmark-based pharmaceutical company focused on medicines for diabetes, obesity, and other serious chronic diseases. It develops, manufactures, and markets prescription medicines and related delivery devices through a global commercial network spanning dozens of countries. ## Products & services • Diabetes medicines, including insulin and GLP-1 therapies • Obesity medicines for chronic weight management • Rare disease treatments such as hemophilia products • Drug delivery devices and pen systems • Research, development, and global commercialization of prescription medicines - **Diabetes care** (60%) — Insulin and other treatments used to manage diabetes and related metabolic disease. - **Obesity care** (25%) — Prescription medicines used for chronic weight management and obesity treatment. - **Rare disease care** (10%) — Specialty therapies for conditions such as hemophilia and other rare disorders. - **Drug delivery devices** (5%) — Injection pens, delivery systems, and supporting devices used with medicines. - Diabetes medicines, including insulin and GLP-1 therapies - Obesity medicines for chronic weight management - Rare disease treatments such as hemophilia products - Drug delivery devices and pen systems - Research, development, and global commercialization of prescription medicines ## Customers Novo Nordisk sells primarily to healthcare systems and prescription medicine channels rather than direct consumers. Its main buyers are hospitals, clinics, pharmacies, distributors, and public or private payers that determine access and reimbursement for chronic disease medicines. Demand is driven by long treatment duration, physician prescribing, and reimbursement coverage for diabetes and obesity therapies. - **Healthcare providers** (primary) — Hospitals, clinics, and specialist centers that prescribe and administer Novo Nordisk medicines. - **Pharmacies and distributors** (primary) — Wholesale and retail channels that purchase finished medicines and deliver them to patients. - **Payers and health systems** (primary) — Government and private reimbursement bodies that influence formulary access and uptake. - **Patients** (secondary) — People using prescribed diabetes, obesity, or rare disease therapies through their providers. - Hospitals and clinics treating diabetes, obesity, and specialty patients - Retail and hospital pharmacies dispensing prescription medicines - Wholesalers and distributors that supply national drug channels - Public and private payers that reimburse chronic disease therapies - Physicians and specialists who prescribe branded injectable medicines ## Geography Novo Nordisk markets its products in around 170 countries and operates with a broad international footprint. Its corporate base is in Denmark, while commercial exposure is diversified across major markets including the United States, Europe, and other international regions. This global footprint matters because reimbursement, regulation, and healthcare access vary materially by country and can affect product mix and demand. - Headquartered in Denmark with global operations centered in Europe - Products marketed in around 170 countries worldwide - United States is a major commercial market and ADR listing venue - Revenue exposure spans Europe, North America, and other international markets - Geographic mix matters because pricing and reimbursement differ by market ## Strategy Novo Nordisk's strategy centers on scientific innovation in chronic disease treatment, especially diabetes and obesity. It also emphasizes expanding access to medicines, scaling global manufacturing and commercial reach, and advancing a pipeline of therapies intended to sustain its position in metabolic and specialty care. - **Pipeline development** (medium-term) — New therapies and label expansions support long-term franchise renewal in chronic disease markets. - **Access and market expansion** (short-term) — Broader reimbursement and country coverage increase patient reach and support prescription volumes. - **Manufacturing and supply scale** (medium-term) — A global injectable medicines business requires dependable capacity and distribution. - **Capital allocation discipline** (short-term) — Share repurchases and treasury management help optimize capital while preserving investment capacity. - Advance diabetes and obesity pipelines through internal R&D - Expand access to medicines across more countries and payers - Scale manufacturing and supply for global demand - Develop and defend specialty franchises in chronic disease - Use capital returns alongside ongoing investment in the business ## Risks Novo Nordisk faces typical pharmaceutical risks around regulation, pricing, and access, because prescriptions depend on payer coverage and government health policy. Company-specific risks include clinical and pipeline setbacks, manufacturing execution for global biologics supply, and legal or reimbursement disputes such as U.S. pricing matters. As a global branded drug company, it is also exposed to patent competition, product concentration, and impairment risk on acquired or developed intangible assets. - **Drug pricing and reimbursement pressure** [high] — Prescription uptake depends on payer coverage and government pricing policy, especially in the U.S. and other major markets. - **Pipeline and clinical development risk** [high] — Late-stage programs can fail, reducing expected future revenues and causing asset write-downs. - **Legal and administrative disputes** [high] — Large pharmaceutical companies face litigation, investigations, and settlement exposure in major markets. - **Manufacturing and supply-chain disruption** [medium] — Global biologics and injectable products require reliable production and distribution. - Drug pricing and reimbursement pressure can limit access and volume growth - Clinical and pipeline failures can impair future growth franchises - Manufacturing or supply disruption can affect global product availability - Legal and regulatory disputes can create one-off charges and uncertainty - Intangible asset impairments can occur when pipeline projects underperform ## Accounting Novo Nordisk's reporting is affected by judgment in estimating rebates, provisions, and impairment losses, especially in the U.S. The interim report also shows that adjusted figures exclude exceptional items such as the reversal of a 340B sales rebate provision and major impairments, which can materially change comparability between periods. - **340B sales rebate provisions** — Reported revenue and adjusted sales comparability - **Intangible asset impairment** — Operating profit and asset carrying values - **Adjusted performance measures** — Investor interpretation of profitability trends - **Treasury shares and buybacks** — EPS, share capital, and equity balance - 340B rebate provisions can materially shift reported sales when reversed - Pipeline intangible impairments directly affect operating profit and asset values - Adjusted results exclude major legal matters and major impairments - Treasury share repurchases affect equity and share count metrics - Interim reporting can create seasonality and quarter-to-quarter comparison noise --- *Last updated: 2026-09-28T12:13:22.303078+00:00*